Sathyanarayana, Padma <br/><br/>
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.  [electronic resource] 

 -  Obesity (Silver Spring, Md.)  Dec 2011 
 - 2310-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1930-739X 
<br/><br/><label>Standard No.: </label>10.1038/oby.2011.152  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adiponectin--blood<br/>Adipose Tissue--drug effects<br/>Alanine Transaminase--blood<br/>Aspartate Aminotransferases--blood<br/>Biomarkers--blood<br/>Blood Glucose--metabolism<br/>Body Mass Index<br/>Body Weight--drug effects<br/>Diabetes Mellitus, Type 2--diet therapy<br/>Drug Therapy, Combination<br/>Exenatide<br/>Fasting<br/>Fatty Acids, Nonesterified--blood<br/>Glucagon-Like Peptide-1 Receptor<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemic Agents--pharmacology<br/>Liver--drug effects<br/>Magnetic Resonance Spectroscopy<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Obesity--complications<br/>PPAR gamma--agonists<br/>Peptides--pharmacology<br/>Pioglitazone<br/>Receptors, Glucagon--agonists<br/>Thiazolidinediones--pharmacology<br/>Triglycerides--blood<br/>Venoms--pharmacology